ImmuCell Q1 Sales Rise 28.4% to $10.4M, Tri-Shield® Up 38.5%
ImmuCell reported preliminary Q1 sales of $10.4 million, marking a 28.4% year-over-year rise driven by a 35.7% jump in domestic revenue to $9.7 million. Tri-Shield® unit sales surged 38.5% to $7.9 million, offsetting a 30.2% drop in international sales to $0.6 million.
1. Q1 Sales Performance
ImmuCell posted $10.4 million in Q1 2026 product sales, up 28.4% from Q1 2025, driven by a 35.7% increase in domestic revenue to $9.7 million. International sales declined 30.2% to $0.6 million, reflecting regional demand challenges.
2. Product Segment Analysis
Tri-Shield® First Defense® sales led the gains with a 38.5% increase to $7.9 million, while Dual-Force® and other products saw a modest 4.4% rise to $2.5 million. The company attributes strong Tri-Shield uptake to peak seasonal demand in the cow-calf segment.
3. Future Outlook and Operations
ImmuCell plans a conference call on May 15 to discuss these results and strategies for recovering from prior backlogs. Management highlighted new hires for international leadership and domestic field sales to support year-round dairy customer growth.